Impact of the introduction of the pneumococcal conjugate vaccine in the Brazilian routine childhood national immunization program
Brazil introduced the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV, Synflorix™, GSK Vaccines) in the routine childhood immunization program in 2010 with a 3+1 schedule (with catch-up for children <2 years-old). This review represents the first an...
Ausführliche Beschreibung
Autor*in: |
Moreira, Marta [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2016transfer abstract |
---|
Schlagwörter: |
---|
Umfang: |
13 |
---|
Übergeordnetes Werk: |
Enthalten in: Quantifying contributions of leaf area and longevity to leaf area duration under increased planting density and nitrogen input regimens during maize yield improvement - Li, Yaoyao ELSEVIER, 2022, Amsterdam |
---|---|
Übergeordnetes Werk: |
volume:34 ; year:2016 ; number:25 ; day:27 ; month:05 ; pages:2766-2778 ; extent:13 |
Links: |
---|
DOI / URN: |
10.1016/j.vaccine.2016.04.006 |
---|
Katalog-ID: |
ELV024363367 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | ELV024363367 | ||
003 | DE-627 | ||
005 | 20230625142731.0 | ||
007 | cr uuu---uuuuu | ||
008 | 180603s2016 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.vaccine.2016.04.006 |2 doi | |
028 | 5 | 2 | |a GBVA2016008000019.pica |
035 | |a (DE-627)ELV024363367 | ||
035 | |a (ELSEVIER)S0264-410X(16)30126-8 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | |a 610 | |
082 | 0 | 4 | |a 610 |q DE-600 |
082 | 0 | 4 | |a 630 |a 640 |q VZ |
084 | |a 48.00 |2 bkl | ||
100 | 1 | |a Moreira, Marta |e verfasserin |4 aut | |
245 | 1 | 0 | |a Impact of the introduction of the pneumococcal conjugate vaccine in the Brazilian routine childhood national immunization program |
264 | 1 | |c 2016transfer abstract | |
300 | |a 13 | ||
336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
337 | |a nicht spezifiziert |b z |2 rdamedia | ||
338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
520 | |a Brazil introduced the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV, Synflorix™, GSK Vaccines) in the routine childhood immunization program in 2010 with a 3+1 schedule (with catch-up for children <2 years-old). This review represents the first analysis of the overall impact of a second-generation pneumococcal conjugate vaccine on nasopharyngeal carriage and all the major pneumococcal disease manifestations in a single, pneumococcal conjugate vaccine-naïve, developing country. A total of 15 published articles and 13 congress abstracts were included in the analysis. In children <5 years-old, studies showed a positive impact of PHiD-CV on the incidence of vaccine-type and any-type invasive pneumococcal disease (including decreases in pneumococcal meningitis morbidity and mortality), on pneumonia incidence and mortality, and on otitis media. Nasopharyngeal carriage of vaccine-type and any-type pneumococci decreased after the primary doses, with no early signs of replacement with other pathogens. Finally, herd protection against vaccine-type invasive pneumococcal disease and pneumonia in unvaccinated subjects was shown in some studies for some age groups. In conclusion, pneumococcal disease decreased after the introduction of PHiD-CV into the Brazilian national immunization program. Further follow-up is needed to evaluate the long-term overall impact of PHiD-CV in the Brazilian population. | ||
520 | |a Brazil introduced the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV, Synflorix™, GSK Vaccines) in the routine childhood immunization program in 2010 with a 3+1 schedule (with catch-up for children <2 years-old). This review represents the first analysis of the overall impact of a second-generation pneumococcal conjugate vaccine on nasopharyngeal carriage and all the major pneumococcal disease manifestations in a single, pneumococcal conjugate vaccine-naïve, developing country. A total of 15 published articles and 13 congress abstracts were included in the analysis. In children <5 years-old, studies showed a positive impact of PHiD-CV on the incidence of vaccine-type and any-type invasive pneumococcal disease (including decreases in pneumococcal meningitis morbidity and mortality), on pneumonia incidence and mortality, and on otitis media. Nasopharyngeal carriage of vaccine-type and any-type pneumococci decreased after the primary doses, with no early signs of replacement with other pathogens. Finally, herd protection against vaccine-type invasive pneumococcal disease and pneumonia in unvaccinated subjects was shown in some studies for some age groups. In conclusion, pneumococcal disease decreased after the introduction of PHiD-CV into the Brazilian national immunization program. Further follow-up is needed to evaluate the long-term overall impact of PHiD-CV in the Brazilian population. | ||
650 | 7 | |a PCV |2 Elsevier | |
650 | 7 | |a NTHi |2 Elsevier | |
650 | 7 | |a NS |2 Elsevier | |
650 | 7 | |a CI |2 Elsevier | |
650 | 7 | |a NVT |2 Elsevier | |
650 | 7 | |a VE |2 Elsevier | |
650 | 7 | |a CVE |2 Elsevier | |
650 | 7 | |a IAL |2 Elsevier | |
650 | 7 | |a RCTs |2 Elsevier | |
650 | 7 | |a SINAN |2 Elsevier | |
650 | 7 | |a PHiD-CV |2 Elsevier | |
650 | 7 | |a IPD |2 Elsevier | |
650 | 7 | |a PM |2 Elsevier | |
650 | 7 | |a VT |2 Elsevier | |
650 | 7 | |a AOM |2 Elsevier | |
700 | 1 | |a Cintra, Otavio |4 oth | |
700 | 1 | |a Harriague, Julie |4 oth | |
700 | 1 | |a Hausdorff, William P. |4 oth | |
700 | 1 | |a Hoet, Bernard |4 oth | |
773 | 0 | 8 | |i Enthalten in |n Elsevier |a Li, Yaoyao ELSEVIER |t Quantifying contributions of leaf area and longevity to leaf area duration under increased planting density and nitrogen input regimens during maize yield improvement |d 2022 |g Amsterdam |w (DE-627)ELV007884451 |
773 | 1 | 8 | |g volume:34 |g year:2016 |g number:25 |g day:27 |g month:05 |g pages:2766-2778 |g extent:13 |
856 | 4 | 0 | |u https://doi.org/10.1016/j.vaccine.2016.04.006 |3 Volltext |
912 | |a GBV_USEFLAG_U | ||
912 | |a GBV_ELV | ||
912 | |a SYSFLAG_U | ||
912 | |a SSG-OPC-FOR | ||
936 | b | k | |a 48.00 |j Land- und Forstwirtschaft: Allgemeines |q VZ |
951 | |a AR | ||
952 | |d 34 |j 2016 |e 25 |b 27 |c 0527 |h 2766-2778 |g 13 | ||
953 | |2 045F |a 610 |
author_variant |
m m mm |
---|---|
matchkey_str |
moreiramartacintraotavioharriaguejulieha:2016----:matfhitoutootenuooclojgtvcienhbaiinotncido |
hierarchy_sort_str |
2016transfer abstract |
bklnumber |
48.00 |
publishDate |
2016 |
allfields |
10.1016/j.vaccine.2016.04.006 doi GBVA2016008000019.pica (DE-627)ELV024363367 (ELSEVIER)S0264-410X(16)30126-8 DE-627 ger DE-627 rakwb eng 610 610 DE-600 630 640 VZ 48.00 bkl Moreira, Marta verfasserin aut Impact of the introduction of the pneumococcal conjugate vaccine in the Brazilian routine childhood national immunization program 2016transfer abstract 13 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Brazil introduced the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV, Synflorix™, GSK Vaccines) in the routine childhood immunization program in 2010 with a 3+1 schedule (with catch-up for children <2 years-old). This review represents the first analysis of the overall impact of a second-generation pneumococcal conjugate vaccine on nasopharyngeal carriage and all the major pneumococcal disease manifestations in a single, pneumococcal conjugate vaccine-naïve, developing country. A total of 15 published articles and 13 congress abstracts were included in the analysis. In children <5 years-old, studies showed a positive impact of PHiD-CV on the incidence of vaccine-type and any-type invasive pneumococcal disease (including decreases in pneumococcal meningitis morbidity and mortality), on pneumonia incidence and mortality, and on otitis media. Nasopharyngeal carriage of vaccine-type and any-type pneumococci decreased after the primary doses, with no early signs of replacement with other pathogens. Finally, herd protection against vaccine-type invasive pneumococcal disease and pneumonia in unvaccinated subjects was shown in some studies for some age groups. In conclusion, pneumococcal disease decreased after the introduction of PHiD-CV into the Brazilian national immunization program. Further follow-up is needed to evaluate the long-term overall impact of PHiD-CV in the Brazilian population. Brazil introduced the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV, Synflorix™, GSK Vaccines) in the routine childhood immunization program in 2010 with a 3+1 schedule (with catch-up for children <2 years-old). This review represents the first analysis of the overall impact of a second-generation pneumococcal conjugate vaccine on nasopharyngeal carriage and all the major pneumococcal disease manifestations in a single, pneumococcal conjugate vaccine-naïve, developing country. A total of 15 published articles and 13 congress abstracts were included in the analysis. In children <5 years-old, studies showed a positive impact of PHiD-CV on the incidence of vaccine-type and any-type invasive pneumococcal disease (including decreases in pneumococcal meningitis morbidity and mortality), on pneumonia incidence and mortality, and on otitis media. Nasopharyngeal carriage of vaccine-type and any-type pneumococci decreased after the primary doses, with no early signs of replacement with other pathogens. Finally, herd protection against vaccine-type invasive pneumococcal disease and pneumonia in unvaccinated subjects was shown in some studies for some age groups. In conclusion, pneumococcal disease decreased after the introduction of PHiD-CV into the Brazilian national immunization program. Further follow-up is needed to evaluate the long-term overall impact of PHiD-CV in the Brazilian population. PCV Elsevier NTHi Elsevier NS Elsevier CI Elsevier NVT Elsevier VE Elsevier CVE Elsevier IAL Elsevier RCTs Elsevier SINAN Elsevier PHiD-CV Elsevier IPD Elsevier PM Elsevier VT Elsevier AOM Elsevier Cintra, Otavio oth Harriague, Julie oth Hausdorff, William P. oth Hoet, Bernard oth Enthalten in Elsevier Li, Yaoyao ELSEVIER Quantifying contributions of leaf area and longevity to leaf area duration under increased planting density and nitrogen input regimens during maize yield improvement 2022 Amsterdam (DE-627)ELV007884451 volume:34 year:2016 number:25 day:27 month:05 pages:2766-2778 extent:13 https://doi.org/10.1016/j.vaccine.2016.04.006 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-FOR 48.00 Land- und Forstwirtschaft: Allgemeines VZ AR 34 2016 25 27 0527 2766-2778 13 045F 610 |
spelling |
10.1016/j.vaccine.2016.04.006 doi GBVA2016008000019.pica (DE-627)ELV024363367 (ELSEVIER)S0264-410X(16)30126-8 DE-627 ger DE-627 rakwb eng 610 610 DE-600 630 640 VZ 48.00 bkl Moreira, Marta verfasserin aut Impact of the introduction of the pneumococcal conjugate vaccine in the Brazilian routine childhood national immunization program 2016transfer abstract 13 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Brazil introduced the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV, Synflorix™, GSK Vaccines) in the routine childhood immunization program in 2010 with a 3+1 schedule (with catch-up for children <2 years-old). This review represents the first analysis of the overall impact of a second-generation pneumococcal conjugate vaccine on nasopharyngeal carriage and all the major pneumococcal disease manifestations in a single, pneumococcal conjugate vaccine-naïve, developing country. A total of 15 published articles and 13 congress abstracts were included in the analysis. In children <5 years-old, studies showed a positive impact of PHiD-CV on the incidence of vaccine-type and any-type invasive pneumococcal disease (including decreases in pneumococcal meningitis morbidity and mortality), on pneumonia incidence and mortality, and on otitis media. Nasopharyngeal carriage of vaccine-type and any-type pneumococci decreased after the primary doses, with no early signs of replacement with other pathogens. Finally, herd protection against vaccine-type invasive pneumococcal disease and pneumonia in unvaccinated subjects was shown in some studies for some age groups. In conclusion, pneumococcal disease decreased after the introduction of PHiD-CV into the Brazilian national immunization program. Further follow-up is needed to evaluate the long-term overall impact of PHiD-CV in the Brazilian population. Brazil introduced the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV, Synflorix™, GSK Vaccines) in the routine childhood immunization program in 2010 with a 3+1 schedule (with catch-up for children <2 years-old). This review represents the first analysis of the overall impact of a second-generation pneumococcal conjugate vaccine on nasopharyngeal carriage and all the major pneumococcal disease manifestations in a single, pneumococcal conjugate vaccine-naïve, developing country. A total of 15 published articles and 13 congress abstracts were included in the analysis. In children <5 years-old, studies showed a positive impact of PHiD-CV on the incidence of vaccine-type and any-type invasive pneumococcal disease (including decreases in pneumococcal meningitis morbidity and mortality), on pneumonia incidence and mortality, and on otitis media. Nasopharyngeal carriage of vaccine-type and any-type pneumococci decreased after the primary doses, with no early signs of replacement with other pathogens. Finally, herd protection against vaccine-type invasive pneumococcal disease and pneumonia in unvaccinated subjects was shown in some studies for some age groups. In conclusion, pneumococcal disease decreased after the introduction of PHiD-CV into the Brazilian national immunization program. Further follow-up is needed to evaluate the long-term overall impact of PHiD-CV in the Brazilian population. PCV Elsevier NTHi Elsevier NS Elsevier CI Elsevier NVT Elsevier VE Elsevier CVE Elsevier IAL Elsevier RCTs Elsevier SINAN Elsevier PHiD-CV Elsevier IPD Elsevier PM Elsevier VT Elsevier AOM Elsevier Cintra, Otavio oth Harriague, Julie oth Hausdorff, William P. oth Hoet, Bernard oth Enthalten in Elsevier Li, Yaoyao ELSEVIER Quantifying contributions of leaf area and longevity to leaf area duration under increased planting density and nitrogen input regimens during maize yield improvement 2022 Amsterdam (DE-627)ELV007884451 volume:34 year:2016 number:25 day:27 month:05 pages:2766-2778 extent:13 https://doi.org/10.1016/j.vaccine.2016.04.006 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-FOR 48.00 Land- und Forstwirtschaft: Allgemeines VZ AR 34 2016 25 27 0527 2766-2778 13 045F 610 |
allfields_unstemmed |
10.1016/j.vaccine.2016.04.006 doi GBVA2016008000019.pica (DE-627)ELV024363367 (ELSEVIER)S0264-410X(16)30126-8 DE-627 ger DE-627 rakwb eng 610 610 DE-600 630 640 VZ 48.00 bkl Moreira, Marta verfasserin aut Impact of the introduction of the pneumococcal conjugate vaccine in the Brazilian routine childhood national immunization program 2016transfer abstract 13 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Brazil introduced the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV, Synflorix™, GSK Vaccines) in the routine childhood immunization program in 2010 with a 3+1 schedule (with catch-up for children <2 years-old). This review represents the first analysis of the overall impact of a second-generation pneumococcal conjugate vaccine on nasopharyngeal carriage and all the major pneumococcal disease manifestations in a single, pneumococcal conjugate vaccine-naïve, developing country. A total of 15 published articles and 13 congress abstracts were included in the analysis. In children <5 years-old, studies showed a positive impact of PHiD-CV on the incidence of vaccine-type and any-type invasive pneumococcal disease (including decreases in pneumococcal meningitis morbidity and mortality), on pneumonia incidence and mortality, and on otitis media. Nasopharyngeal carriage of vaccine-type and any-type pneumococci decreased after the primary doses, with no early signs of replacement with other pathogens. Finally, herd protection against vaccine-type invasive pneumococcal disease and pneumonia in unvaccinated subjects was shown in some studies for some age groups. In conclusion, pneumococcal disease decreased after the introduction of PHiD-CV into the Brazilian national immunization program. Further follow-up is needed to evaluate the long-term overall impact of PHiD-CV in the Brazilian population. Brazil introduced the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV, Synflorix™, GSK Vaccines) in the routine childhood immunization program in 2010 with a 3+1 schedule (with catch-up for children <2 years-old). This review represents the first analysis of the overall impact of a second-generation pneumococcal conjugate vaccine on nasopharyngeal carriage and all the major pneumococcal disease manifestations in a single, pneumococcal conjugate vaccine-naïve, developing country. A total of 15 published articles and 13 congress abstracts were included in the analysis. In children <5 years-old, studies showed a positive impact of PHiD-CV on the incidence of vaccine-type and any-type invasive pneumococcal disease (including decreases in pneumococcal meningitis morbidity and mortality), on pneumonia incidence and mortality, and on otitis media. Nasopharyngeal carriage of vaccine-type and any-type pneumococci decreased after the primary doses, with no early signs of replacement with other pathogens. Finally, herd protection against vaccine-type invasive pneumococcal disease and pneumonia in unvaccinated subjects was shown in some studies for some age groups. In conclusion, pneumococcal disease decreased after the introduction of PHiD-CV into the Brazilian national immunization program. Further follow-up is needed to evaluate the long-term overall impact of PHiD-CV in the Brazilian population. PCV Elsevier NTHi Elsevier NS Elsevier CI Elsevier NVT Elsevier VE Elsevier CVE Elsevier IAL Elsevier RCTs Elsevier SINAN Elsevier PHiD-CV Elsevier IPD Elsevier PM Elsevier VT Elsevier AOM Elsevier Cintra, Otavio oth Harriague, Julie oth Hausdorff, William P. oth Hoet, Bernard oth Enthalten in Elsevier Li, Yaoyao ELSEVIER Quantifying contributions of leaf area and longevity to leaf area duration under increased planting density and nitrogen input regimens during maize yield improvement 2022 Amsterdam (DE-627)ELV007884451 volume:34 year:2016 number:25 day:27 month:05 pages:2766-2778 extent:13 https://doi.org/10.1016/j.vaccine.2016.04.006 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-FOR 48.00 Land- und Forstwirtschaft: Allgemeines VZ AR 34 2016 25 27 0527 2766-2778 13 045F 610 |
allfieldsGer |
10.1016/j.vaccine.2016.04.006 doi GBVA2016008000019.pica (DE-627)ELV024363367 (ELSEVIER)S0264-410X(16)30126-8 DE-627 ger DE-627 rakwb eng 610 610 DE-600 630 640 VZ 48.00 bkl Moreira, Marta verfasserin aut Impact of the introduction of the pneumococcal conjugate vaccine in the Brazilian routine childhood national immunization program 2016transfer abstract 13 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Brazil introduced the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV, Synflorix™, GSK Vaccines) in the routine childhood immunization program in 2010 with a 3+1 schedule (with catch-up for children <2 years-old). This review represents the first analysis of the overall impact of a second-generation pneumococcal conjugate vaccine on nasopharyngeal carriage and all the major pneumococcal disease manifestations in a single, pneumococcal conjugate vaccine-naïve, developing country. A total of 15 published articles and 13 congress abstracts were included in the analysis. In children <5 years-old, studies showed a positive impact of PHiD-CV on the incidence of vaccine-type and any-type invasive pneumococcal disease (including decreases in pneumococcal meningitis morbidity and mortality), on pneumonia incidence and mortality, and on otitis media. Nasopharyngeal carriage of vaccine-type and any-type pneumococci decreased after the primary doses, with no early signs of replacement with other pathogens. Finally, herd protection against vaccine-type invasive pneumococcal disease and pneumonia in unvaccinated subjects was shown in some studies for some age groups. In conclusion, pneumococcal disease decreased after the introduction of PHiD-CV into the Brazilian national immunization program. Further follow-up is needed to evaluate the long-term overall impact of PHiD-CV in the Brazilian population. Brazil introduced the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV, Synflorix™, GSK Vaccines) in the routine childhood immunization program in 2010 with a 3+1 schedule (with catch-up for children <2 years-old). This review represents the first analysis of the overall impact of a second-generation pneumococcal conjugate vaccine on nasopharyngeal carriage and all the major pneumococcal disease manifestations in a single, pneumococcal conjugate vaccine-naïve, developing country. A total of 15 published articles and 13 congress abstracts were included in the analysis. In children <5 years-old, studies showed a positive impact of PHiD-CV on the incidence of vaccine-type and any-type invasive pneumococcal disease (including decreases in pneumococcal meningitis morbidity and mortality), on pneumonia incidence and mortality, and on otitis media. Nasopharyngeal carriage of vaccine-type and any-type pneumococci decreased after the primary doses, with no early signs of replacement with other pathogens. Finally, herd protection against vaccine-type invasive pneumococcal disease and pneumonia in unvaccinated subjects was shown in some studies for some age groups. In conclusion, pneumococcal disease decreased after the introduction of PHiD-CV into the Brazilian national immunization program. Further follow-up is needed to evaluate the long-term overall impact of PHiD-CV in the Brazilian population. PCV Elsevier NTHi Elsevier NS Elsevier CI Elsevier NVT Elsevier VE Elsevier CVE Elsevier IAL Elsevier RCTs Elsevier SINAN Elsevier PHiD-CV Elsevier IPD Elsevier PM Elsevier VT Elsevier AOM Elsevier Cintra, Otavio oth Harriague, Julie oth Hausdorff, William P. oth Hoet, Bernard oth Enthalten in Elsevier Li, Yaoyao ELSEVIER Quantifying contributions of leaf area and longevity to leaf area duration under increased planting density and nitrogen input regimens during maize yield improvement 2022 Amsterdam (DE-627)ELV007884451 volume:34 year:2016 number:25 day:27 month:05 pages:2766-2778 extent:13 https://doi.org/10.1016/j.vaccine.2016.04.006 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-FOR 48.00 Land- und Forstwirtschaft: Allgemeines VZ AR 34 2016 25 27 0527 2766-2778 13 045F 610 |
allfieldsSound |
10.1016/j.vaccine.2016.04.006 doi GBVA2016008000019.pica (DE-627)ELV024363367 (ELSEVIER)S0264-410X(16)30126-8 DE-627 ger DE-627 rakwb eng 610 610 DE-600 630 640 VZ 48.00 bkl Moreira, Marta verfasserin aut Impact of the introduction of the pneumococcal conjugate vaccine in the Brazilian routine childhood national immunization program 2016transfer abstract 13 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Brazil introduced the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV, Synflorix™, GSK Vaccines) in the routine childhood immunization program in 2010 with a 3+1 schedule (with catch-up for children <2 years-old). This review represents the first analysis of the overall impact of a second-generation pneumococcal conjugate vaccine on nasopharyngeal carriage and all the major pneumococcal disease manifestations in a single, pneumococcal conjugate vaccine-naïve, developing country. A total of 15 published articles and 13 congress abstracts were included in the analysis. In children <5 years-old, studies showed a positive impact of PHiD-CV on the incidence of vaccine-type and any-type invasive pneumococcal disease (including decreases in pneumococcal meningitis morbidity and mortality), on pneumonia incidence and mortality, and on otitis media. Nasopharyngeal carriage of vaccine-type and any-type pneumococci decreased after the primary doses, with no early signs of replacement with other pathogens. Finally, herd protection against vaccine-type invasive pneumococcal disease and pneumonia in unvaccinated subjects was shown in some studies for some age groups. In conclusion, pneumococcal disease decreased after the introduction of PHiD-CV into the Brazilian national immunization program. Further follow-up is needed to evaluate the long-term overall impact of PHiD-CV in the Brazilian population. Brazil introduced the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV, Synflorix™, GSK Vaccines) in the routine childhood immunization program in 2010 with a 3+1 schedule (with catch-up for children <2 years-old). This review represents the first analysis of the overall impact of a second-generation pneumococcal conjugate vaccine on nasopharyngeal carriage and all the major pneumococcal disease manifestations in a single, pneumococcal conjugate vaccine-naïve, developing country. A total of 15 published articles and 13 congress abstracts were included in the analysis. In children <5 years-old, studies showed a positive impact of PHiD-CV on the incidence of vaccine-type and any-type invasive pneumococcal disease (including decreases in pneumococcal meningitis morbidity and mortality), on pneumonia incidence and mortality, and on otitis media. Nasopharyngeal carriage of vaccine-type and any-type pneumococci decreased after the primary doses, with no early signs of replacement with other pathogens. Finally, herd protection against vaccine-type invasive pneumococcal disease and pneumonia in unvaccinated subjects was shown in some studies for some age groups. In conclusion, pneumococcal disease decreased after the introduction of PHiD-CV into the Brazilian national immunization program. Further follow-up is needed to evaluate the long-term overall impact of PHiD-CV in the Brazilian population. PCV Elsevier NTHi Elsevier NS Elsevier CI Elsevier NVT Elsevier VE Elsevier CVE Elsevier IAL Elsevier RCTs Elsevier SINAN Elsevier PHiD-CV Elsevier IPD Elsevier PM Elsevier VT Elsevier AOM Elsevier Cintra, Otavio oth Harriague, Julie oth Hausdorff, William P. oth Hoet, Bernard oth Enthalten in Elsevier Li, Yaoyao ELSEVIER Quantifying contributions of leaf area and longevity to leaf area duration under increased planting density and nitrogen input regimens during maize yield improvement 2022 Amsterdam (DE-627)ELV007884451 volume:34 year:2016 number:25 day:27 month:05 pages:2766-2778 extent:13 https://doi.org/10.1016/j.vaccine.2016.04.006 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-FOR 48.00 Land- und Forstwirtschaft: Allgemeines VZ AR 34 2016 25 27 0527 2766-2778 13 045F 610 |
language |
English |
source |
Enthalten in Quantifying contributions of leaf area and longevity to leaf area duration under increased planting density and nitrogen input regimens during maize yield improvement Amsterdam volume:34 year:2016 number:25 day:27 month:05 pages:2766-2778 extent:13 |
sourceStr |
Enthalten in Quantifying contributions of leaf area and longevity to leaf area duration under increased planting density and nitrogen input regimens during maize yield improvement Amsterdam volume:34 year:2016 number:25 day:27 month:05 pages:2766-2778 extent:13 |
format_phy_str_mv |
Article |
bklname |
Land- und Forstwirtschaft: Allgemeines |
institution |
findex.gbv.de |
topic_facet |
PCV NTHi NS CI NVT VE CVE IAL RCTs SINAN PHiD-CV IPD PM VT AOM |
dewey-raw |
610 |
isfreeaccess_bool |
false |
container_title |
Quantifying contributions of leaf area and longevity to leaf area duration under increased planting density and nitrogen input regimens during maize yield improvement |
authorswithroles_txt_mv |
Moreira, Marta @@aut@@ Cintra, Otavio @@oth@@ Harriague, Julie @@oth@@ Hausdorff, William P. @@oth@@ Hoet, Bernard @@oth@@ |
publishDateDaySort_date |
2016-01-27T00:00:00Z |
hierarchy_top_id |
ELV007884451 |
dewey-sort |
3610 |
id |
ELV024363367 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV024363367</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625142731.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.vaccine.2016.04.006</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2016008000019.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV024363367</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0264-410X(16)30126-8</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">630</subfield><subfield code="a">640</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">48.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Moreira, Marta</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Impact of the introduction of the pneumococcal conjugate vaccine in the Brazilian routine childhood national immunization program</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">13</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Brazil introduced the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV, Synflorix™, GSK Vaccines) in the routine childhood immunization program in 2010 with a 3+1 schedule (with catch-up for children <2 years-old). This review represents the first analysis of the overall impact of a second-generation pneumococcal conjugate vaccine on nasopharyngeal carriage and all the major pneumococcal disease manifestations in a single, pneumococcal conjugate vaccine-naïve, developing country. A total of 15 published articles and 13 congress abstracts were included in the analysis. In children <5 years-old, studies showed a positive impact of PHiD-CV on the incidence of vaccine-type and any-type invasive pneumococcal disease (including decreases in pneumococcal meningitis morbidity and mortality), on pneumonia incidence and mortality, and on otitis media. Nasopharyngeal carriage of vaccine-type and any-type pneumococci decreased after the primary doses, with no early signs of replacement with other pathogens. Finally, herd protection against vaccine-type invasive pneumococcal disease and pneumonia in unvaccinated subjects was shown in some studies for some age groups. In conclusion, pneumococcal disease decreased after the introduction of PHiD-CV into the Brazilian national immunization program. Further follow-up is needed to evaluate the long-term overall impact of PHiD-CV in the Brazilian population.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Brazil introduced the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV, Synflorix™, GSK Vaccines) in the routine childhood immunization program in 2010 with a 3+1 schedule (with catch-up for children <2 years-old). This review represents the first analysis of the overall impact of a second-generation pneumococcal conjugate vaccine on nasopharyngeal carriage and all the major pneumococcal disease manifestations in a single, pneumococcal conjugate vaccine-naïve, developing country. A total of 15 published articles and 13 congress abstracts were included in the analysis. In children <5 years-old, studies showed a positive impact of PHiD-CV on the incidence of vaccine-type and any-type invasive pneumococcal disease (including decreases in pneumococcal meningitis morbidity and mortality), on pneumonia incidence and mortality, and on otitis media. Nasopharyngeal carriage of vaccine-type and any-type pneumococci decreased after the primary doses, with no early signs of replacement with other pathogens. Finally, herd protection against vaccine-type invasive pneumococcal disease and pneumonia in unvaccinated subjects was shown in some studies for some age groups. In conclusion, pneumococcal disease decreased after the introduction of PHiD-CV into the Brazilian national immunization program. Further follow-up is needed to evaluate the long-term overall impact of PHiD-CV in the Brazilian population.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PCV</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">NTHi</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">NS</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CI</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">NVT</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">VE</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CVE</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">IAL</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">RCTs</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SINAN</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PHiD-CV</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">IPD</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PM</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">VT</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">AOM</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cintra, Otavio</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Harriague, Julie</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hausdorff, William P.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hoet, Bernard</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Li, Yaoyao ELSEVIER</subfield><subfield code="t">Quantifying contributions of leaf area and longevity to leaf area duration under increased planting density and nitrogen input regimens during maize yield improvement</subfield><subfield code="d">2022</subfield><subfield code="g">Amsterdam</subfield><subfield code="w">(DE-627)ELV007884451</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:34</subfield><subfield code="g">year:2016</subfield><subfield code="g">number:25</subfield><subfield code="g">day:27</subfield><subfield code="g">month:05</subfield><subfield code="g">pages:2766-2778</subfield><subfield code="g">extent:13</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.vaccine.2016.04.006</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-FOR</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">48.00</subfield><subfield code="j">Land- und Forstwirtschaft: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">34</subfield><subfield code="j">2016</subfield><subfield code="e">25</subfield><subfield code="b">27</subfield><subfield code="c">0527</subfield><subfield code="h">2766-2778</subfield><subfield code="g">13</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
author |
Moreira, Marta |
spellingShingle |
Moreira, Marta ddc 610 ddc 630 bkl 48.00 Elsevier PCV Elsevier NTHi Elsevier NS Elsevier CI Elsevier NVT Elsevier VE Elsevier CVE Elsevier IAL Elsevier RCTs Elsevier SINAN Elsevier PHiD-CV Elsevier IPD Elsevier PM Elsevier VT Elsevier AOM Impact of the introduction of the pneumococcal conjugate vaccine in the Brazilian routine childhood national immunization program |
authorStr |
Moreira, Marta |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV007884451 |
format |
electronic Article |
dewey-ones |
610 - Medicine & health 630 - Agriculture & related technologies 640 - Home & family management |
delete_txt_mv |
keep |
author_role |
aut |
collection |
elsevier |
remote_str |
true |
illustrated |
Not Illustrated |
topic_title |
610 610 DE-600 630 640 VZ 48.00 bkl Impact of the introduction of the pneumococcal conjugate vaccine in the Brazilian routine childhood national immunization program PCV Elsevier NTHi Elsevier NS Elsevier CI Elsevier NVT Elsevier VE Elsevier CVE Elsevier IAL Elsevier RCTs Elsevier SINAN Elsevier PHiD-CV Elsevier IPD Elsevier PM Elsevier VT Elsevier AOM Elsevier |
topic |
ddc 610 ddc 630 bkl 48.00 Elsevier PCV Elsevier NTHi Elsevier NS Elsevier CI Elsevier NVT Elsevier VE Elsevier CVE Elsevier IAL Elsevier RCTs Elsevier SINAN Elsevier PHiD-CV Elsevier IPD Elsevier PM Elsevier VT Elsevier AOM |
topic_unstemmed |
ddc 610 ddc 630 bkl 48.00 Elsevier PCV Elsevier NTHi Elsevier NS Elsevier CI Elsevier NVT Elsevier VE Elsevier CVE Elsevier IAL Elsevier RCTs Elsevier SINAN Elsevier PHiD-CV Elsevier IPD Elsevier PM Elsevier VT Elsevier AOM |
topic_browse |
ddc 610 ddc 630 bkl 48.00 Elsevier PCV Elsevier NTHi Elsevier NS Elsevier CI Elsevier NVT Elsevier VE Elsevier CVE Elsevier IAL Elsevier RCTs Elsevier SINAN Elsevier PHiD-CV Elsevier IPD Elsevier PM Elsevier VT Elsevier AOM |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
zu |
author2_variant |
o c oc j h jh w p h wp wph b h bh |
hierarchy_parent_title |
Quantifying contributions of leaf area and longevity to leaf area duration under increased planting density and nitrogen input regimens during maize yield improvement |
hierarchy_parent_id |
ELV007884451 |
dewey-tens |
610 - Medicine & health 630 - Agriculture 640 - Home & family management |
hierarchy_top_title |
Quantifying contributions of leaf area and longevity to leaf area duration under increased planting density and nitrogen input regimens during maize yield improvement |
isfreeaccess_txt |
false |
familylinks_str_mv |
(DE-627)ELV007884451 |
title |
Impact of the introduction of the pneumococcal conjugate vaccine in the Brazilian routine childhood national immunization program |
ctrlnum |
(DE-627)ELV024363367 (ELSEVIER)S0264-410X(16)30126-8 |
title_full |
Impact of the introduction of the pneumococcal conjugate vaccine in the Brazilian routine childhood national immunization program |
author_sort |
Moreira, Marta |
journal |
Quantifying contributions of leaf area and longevity to leaf area duration under increased planting density and nitrogen input regimens during maize yield improvement |
journalStr |
Quantifying contributions of leaf area and longevity to leaf area duration under increased planting density and nitrogen input regimens during maize yield improvement |
lang_code |
eng |
isOA_bool |
false |
dewey-hundreds |
600 - Technology |
recordtype |
marc |
publishDateSort |
2016 |
contenttype_str_mv |
zzz |
container_start_page |
2766 |
author_browse |
Moreira, Marta |
container_volume |
34 |
physical |
13 |
class |
610 610 DE-600 630 640 VZ 48.00 bkl |
format_se |
Elektronische Aufsätze |
author-letter |
Moreira, Marta |
doi_str_mv |
10.1016/j.vaccine.2016.04.006 |
dewey-full |
610 630 640 |
title_sort |
impact of the introduction of the pneumococcal conjugate vaccine in the brazilian routine childhood national immunization program |
title_auth |
Impact of the introduction of the pneumococcal conjugate vaccine in the Brazilian routine childhood national immunization program |
abstract |
Brazil introduced the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV, Synflorix™, GSK Vaccines) in the routine childhood immunization program in 2010 with a 3+1 schedule (with catch-up for children <2 years-old). This review represents the first analysis of the overall impact of a second-generation pneumococcal conjugate vaccine on nasopharyngeal carriage and all the major pneumococcal disease manifestations in a single, pneumococcal conjugate vaccine-naïve, developing country. A total of 15 published articles and 13 congress abstracts were included in the analysis. In children <5 years-old, studies showed a positive impact of PHiD-CV on the incidence of vaccine-type and any-type invasive pneumococcal disease (including decreases in pneumococcal meningitis morbidity and mortality), on pneumonia incidence and mortality, and on otitis media. Nasopharyngeal carriage of vaccine-type and any-type pneumococci decreased after the primary doses, with no early signs of replacement with other pathogens. Finally, herd protection against vaccine-type invasive pneumococcal disease and pneumonia in unvaccinated subjects was shown in some studies for some age groups. In conclusion, pneumococcal disease decreased after the introduction of PHiD-CV into the Brazilian national immunization program. Further follow-up is needed to evaluate the long-term overall impact of PHiD-CV in the Brazilian population. |
abstractGer |
Brazil introduced the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV, Synflorix™, GSK Vaccines) in the routine childhood immunization program in 2010 with a 3+1 schedule (with catch-up for children <2 years-old). This review represents the first analysis of the overall impact of a second-generation pneumococcal conjugate vaccine on nasopharyngeal carriage and all the major pneumococcal disease manifestations in a single, pneumococcal conjugate vaccine-naïve, developing country. A total of 15 published articles and 13 congress abstracts were included in the analysis. In children <5 years-old, studies showed a positive impact of PHiD-CV on the incidence of vaccine-type and any-type invasive pneumococcal disease (including decreases in pneumococcal meningitis morbidity and mortality), on pneumonia incidence and mortality, and on otitis media. Nasopharyngeal carriage of vaccine-type and any-type pneumococci decreased after the primary doses, with no early signs of replacement with other pathogens. Finally, herd protection against vaccine-type invasive pneumococcal disease and pneumonia in unvaccinated subjects was shown in some studies for some age groups. In conclusion, pneumococcal disease decreased after the introduction of PHiD-CV into the Brazilian national immunization program. Further follow-up is needed to evaluate the long-term overall impact of PHiD-CV in the Brazilian population. |
abstract_unstemmed |
Brazil introduced the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV, Synflorix™, GSK Vaccines) in the routine childhood immunization program in 2010 with a 3+1 schedule (with catch-up for children <2 years-old). This review represents the first analysis of the overall impact of a second-generation pneumococcal conjugate vaccine on nasopharyngeal carriage and all the major pneumococcal disease manifestations in a single, pneumococcal conjugate vaccine-naïve, developing country. A total of 15 published articles and 13 congress abstracts were included in the analysis. In children <5 years-old, studies showed a positive impact of PHiD-CV on the incidence of vaccine-type and any-type invasive pneumococcal disease (including decreases in pneumococcal meningitis morbidity and mortality), on pneumonia incidence and mortality, and on otitis media. Nasopharyngeal carriage of vaccine-type and any-type pneumococci decreased after the primary doses, with no early signs of replacement with other pathogens. Finally, herd protection against vaccine-type invasive pneumococcal disease and pneumonia in unvaccinated subjects was shown in some studies for some age groups. In conclusion, pneumococcal disease decreased after the introduction of PHiD-CV into the Brazilian national immunization program. Further follow-up is needed to evaluate the long-term overall impact of PHiD-CV in the Brazilian population. |
collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-FOR |
container_issue |
25 |
title_short |
Impact of the introduction of the pneumococcal conjugate vaccine in the Brazilian routine childhood national immunization program |
url |
https://doi.org/10.1016/j.vaccine.2016.04.006 |
remote_bool |
true |
author2 |
Cintra, Otavio Harriague, Julie Hausdorff, William P. Hoet, Bernard |
author2Str |
Cintra, Otavio Harriague, Julie Hausdorff, William P. Hoet, Bernard |
ppnlink |
ELV007884451 |
mediatype_str_mv |
z |
isOA_txt |
false |
hochschulschrift_bool |
false |
author2_role |
oth oth oth oth |
doi_str |
10.1016/j.vaccine.2016.04.006 |
up_date |
2024-07-06T21:14:24.374Z |
_version_ |
1803865779732480000 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV024363367</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625142731.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.vaccine.2016.04.006</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2016008000019.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV024363367</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0264-410X(16)30126-8</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">630</subfield><subfield code="a">640</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">48.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Moreira, Marta</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Impact of the introduction of the pneumococcal conjugate vaccine in the Brazilian routine childhood national immunization program</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">13</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Brazil introduced the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV, Synflorix™, GSK Vaccines) in the routine childhood immunization program in 2010 with a 3+1 schedule (with catch-up for children <2 years-old). This review represents the first analysis of the overall impact of a second-generation pneumococcal conjugate vaccine on nasopharyngeal carriage and all the major pneumococcal disease manifestations in a single, pneumococcal conjugate vaccine-naïve, developing country. A total of 15 published articles and 13 congress abstracts were included in the analysis. In children <5 years-old, studies showed a positive impact of PHiD-CV on the incidence of vaccine-type and any-type invasive pneumococcal disease (including decreases in pneumococcal meningitis morbidity and mortality), on pneumonia incidence and mortality, and on otitis media. Nasopharyngeal carriage of vaccine-type and any-type pneumococci decreased after the primary doses, with no early signs of replacement with other pathogens. Finally, herd protection against vaccine-type invasive pneumococcal disease and pneumonia in unvaccinated subjects was shown in some studies for some age groups. In conclusion, pneumococcal disease decreased after the introduction of PHiD-CV into the Brazilian national immunization program. Further follow-up is needed to evaluate the long-term overall impact of PHiD-CV in the Brazilian population.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Brazil introduced the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV, Synflorix™, GSK Vaccines) in the routine childhood immunization program in 2010 with a 3+1 schedule (with catch-up for children <2 years-old). This review represents the first analysis of the overall impact of a second-generation pneumococcal conjugate vaccine on nasopharyngeal carriage and all the major pneumococcal disease manifestations in a single, pneumococcal conjugate vaccine-naïve, developing country. A total of 15 published articles and 13 congress abstracts were included in the analysis. In children <5 years-old, studies showed a positive impact of PHiD-CV on the incidence of vaccine-type and any-type invasive pneumococcal disease (including decreases in pneumococcal meningitis morbidity and mortality), on pneumonia incidence and mortality, and on otitis media. Nasopharyngeal carriage of vaccine-type and any-type pneumococci decreased after the primary doses, with no early signs of replacement with other pathogens. Finally, herd protection against vaccine-type invasive pneumococcal disease and pneumonia in unvaccinated subjects was shown in some studies for some age groups. In conclusion, pneumococcal disease decreased after the introduction of PHiD-CV into the Brazilian national immunization program. Further follow-up is needed to evaluate the long-term overall impact of PHiD-CV in the Brazilian population.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PCV</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">NTHi</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">NS</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CI</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">NVT</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">VE</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CVE</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">IAL</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">RCTs</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SINAN</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PHiD-CV</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">IPD</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PM</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">VT</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">AOM</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cintra, Otavio</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Harriague, Julie</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hausdorff, William P.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hoet, Bernard</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Li, Yaoyao ELSEVIER</subfield><subfield code="t">Quantifying contributions of leaf area and longevity to leaf area duration under increased planting density and nitrogen input regimens during maize yield improvement</subfield><subfield code="d">2022</subfield><subfield code="g">Amsterdam</subfield><subfield code="w">(DE-627)ELV007884451</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:34</subfield><subfield code="g">year:2016</subfield><subfield code="g">number:25</subfield><subfield code="g">day:27</subfield><subfield code="g">month:05</subfield><subfield code="g">pages:2766-2778</subfield><subfield code="g">extent:13</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.vaccine.2016.04.006</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-FOR</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">48.00</subfield><subfield code="j">Land- und Forstwirtschaft: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">34</subfield><subfield code="j">2016</subfield><subfield code="e">25</subfield><subfield code="b">27</subfield><subfield code="c">0527</subfield><subfield code="h">2766-2778</subfield><subfield code="g">13</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
score |
7.400485 |